{"component": "definition", "props": {"groups": [{"snippet": "has the meaning set forth in Section 3.5.3 (Decision-Making).", "samples": [{"hash": "ammFydaOpA2", "uri": "/contracts/ammFydaOpA2#expert-panel", "label": "Collaboration Agreement (Soaring Eagle Acquisition Corp.)", "score": 32.4880218506, "published": true}, {"hash": "bfP428X4lPO", "uri": "/contracts/bfP428X4lPO#expert-panel", "label": "Collaboration Agreement (Berkeley Lights, Inc.)", "score": 31.4832305908, "published": true}], "snippet_links": [{"key": "section-353", "type": "clause", "offset": [29, 42]}], "size": 6, "hash": "cf72d903b7ea22528dde1ab8ff2b28a1", "id": 1}, {"snippet": "means a pool of independent medical experts with appropriate knowledge and expertise, appointed by UCI to perform the functions set out in these Regulations on the Eligibility of Transgender Athletes, which will review cases arising under these Regulations.", "samples": [{"hash": "fhr4Chdhesg", "uri": "https://jcf.or.jp/wp2012/wp-content/uploads/downloads/2023/10/13_medical_rules_20230714.pdf", "label": "jcf.or.jp", "score": 16.8585681915, "published": false}, {"hash": "8XLcR09gKTm", "uri": "https://assets.ctfassets.net/761l7gh5x5an/3PksS8vqCVRmQnSfcLy3qk/149a8cfeb5172733e1a2aee410c0448e/13-SEC-2024-02-05-ENG-All_in_Black.pdf", "label": "assets.ctfassets.net", "score": 15.6841802597, "published": false}, {"hash": "b9GLWw5T69q", "uri": "https://assets.ctfassets.net/761l7gh5x5an/3PksS8vqCVRmQnSfcLy3qk/a2b478aa5fbf3a9c4a5a488090c51c4c/13-SEC-2023-07-17-ENG.pdf", "label": "assets.ctfassets.net", "score": 8.7707052231, "published": false}], "snippet_links": [{"key": "independent-medical", "type": "clause", "offset": [16, 35]}, {"key": "the-functions", "type": "definition", "offset": [114, 127]}, {"key": "set-out", "type": "definition", "offset": [128, 135]}, {"key": "these-regulations", "type": "definition", "offset": [139, 156]}], "size": 4, "hash": "4641c290250ae6560012615a23a53e14", "id": 2}, {"snippet": "is defined in Section 19.2.2 (Establishment and Operation of Expert Panel).", "samples": [{"hash": "4CdPCpiVXPg", "uri": "/contracts/4CdPCpiVXPg#expert-panel", "label": "Partnership Agreement", "score": 33.3756370544, "published": true}, {"hash": "ljZL5E6fF4C", "uri": "/contracts/ljZL5E6fF4C#expert-panel", "label": "Sample Contract", "score": 21.4175224304, "published": true}, {"hash": "3uRWZqizNk6", "uri": "/contracts/3uRWZqizNk6#expert-panel", "label": "Sample Contract", "score": 21.4175224304, "published": true}], "snippet_links": [{"key": "section-1922", "type": "clause", "offset": [14, 28]}, {"key": "establishment-and-operation-of-expert-panel", "type": "clause", "offset": [30, 73]}], "size": 4, "hash": "d511620fa52edecacc45b9908fd3763f", "id": 3}, {"snippet": "means a panel established in accordance with paragraph 6;", "samples": [{"hash": "cUfJlQjBhBQ", "uri": "https://www.legislation.gov.uk/cy/ukpga/2018/29/data.pdf", "label": "www.legislation.gov.uk", "score": 9.9479808807, "published": false}, {"hash": "ixLHiWMsW8N", "uri": "https://www.legislation.gov.uk/ukpga/2018/29/data.pdf", "label": "www.legislation.gov.uk", "score": 9.7563314438, "published": false}, {"hash": "eE6c5FPljn5", "uri": "https://www.lawsoc-ni.org/DatabaseDocs/nav_2885462__updated_paper.docx", "label": "www.lawsoc-ni.org", "score": 7.637919426, "published": false}], "snippet_links": [{"key": "a-panel", "type": "definition", "offset": [6, 13]}, {"key": "in-accordance-with", "type": "definition", "offset": [26, 44]}, {"key": "paragraph-6", "type": "definition", "offset": [45, 56]}], "size": 3, "hash": "8d47adedef9d4b32c05fb9738cbe19ee", "id": 4}, {"snippet": "shall have the meaning assigned to such term in Section 2.4.", "samples": [{"hash": "jXarcyyTxOx", "uri": "/contracts/jXarcyyTxOx#expert-panel", "label": "Product Development and Commercialization Agreement (Regulus Therapeutics Inc.)", "score": 23.7132110596, "published": true}, {"hash": "7LhGaAWILVC", "uri": "/contracts/7LhGaAWILVC#expert-panel", "label": "Product Development and Commercialization Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989075, "published": true}, {"hash": "582XcPEuftW", "uri": "/contracts/582XcPEuftW#expert-panel", "label": "Product Development and Commercialization Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "section-24", "type": "definition", "offset": [48, 59]}], "size": 3, "hash": "14618877db0f69607f64a625e073fdc1", "id": 5}, {"snippet": "means a panel established in accordance with paragraph 6; \u201crate determination\u201d has the meaning given by paragraph 4;", "samples": [{"hash": "lO4CRjoTCvP", "uri": "https://www.legislation.gov.uk/ukpga/1996/48/data.pdf?view=extent", "label": "www.legislation.gov.uk", "score": 11.3216972351, "published": false}, {"hash": "42T7fpsOgDS", "uri": "https://www.legislation.gov.uk/ukpga/1996/48/data.pdf", "label": "www.legislation.gov.uk", "score": 10.7973985672, "published": false}, {"hash": "gI9eJNrD1zT", "uri": "https://www.legislation.gov.uk/ukpga/1996/48/schedules/data.pdf", "label": "www.legislation.gov.uk", "score": 9.2039699554, "published": false}], "snippet_links": [{"key": "a-panel", "type": "definition", "offset": [6, 13]}, {"key": "in-accordance-with", "type": "definition", "offset": [26, 44]}, {"key": "paragraph-6", "type": "definition", "offset": [45, 56]}, {"key": "rate-determination", "type": "clause", "offset": [59, 77]}, {"key": "paragraph-4", "type": "definition", "offset": [104, 115]}], "size": 3, "hash": "9be5e4c0cd94c659f47537325179f431", "id": 6}, {"snippet": "shall have the meaning set forth in Section 10.4.", "samples": [{"hash": "2UN3ciuaAyX", "uri": "/contracts/2UN3ciuaAyX#expert-panel", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "eLXwMP3BD51", "uri": "/contracts/eLXwMP3BD51#expert-panel", "label": "Collaboration Agreement (Regeneron Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [], "size": 2, "hash": "58a5af42798697f97a773f55c827866d", "id": 7}, {"snippet": "means an expert panel of the Institution for the time being.", "samples": [{"hash": "4oN6okvd1Ho", "uri": "https://www.ciwem.org/assets/pdf/assets/uploads/Byelaws.pdf", "label": "www.ciwem.org", "score": 11.1843385696, "published": false}, {"hash": "cqKs2DhW91s", "uri": "https://www.ciwem.org/assets/uploads/Royal_Charter_and_Bye_Laws_26.10.21_1.pdf", "label": "www.ciwem.org", "score": 9.7405881882, "published": false}], "snippet_links": [{"key": "the-institution", "type": "clause", "offset": [25, 40]}], "size": 2, "hash": "5961980fbad2e77619a9ff4ecd8744a6", "id": 8}, {"snippet": "shall have the meaning given to it in the License Agreement Disputes between the Parties under this Agreement that are eligible to be referred to an Expert Panel shall be resolved in accordance with the provisions set forth in Section 3.5(c)(iii) of the License Agreement.", "samples": [{"hash": "5c5uuoTBGvQ", "uri": "/contracts/5c5uuoTBGvQ#expert-panel", "label": "Supply Agreement (Acorda Therapeutics Inc)", "score": 25.5968513489, "published": true}, {"hash": "fF5AoXOTwNf", "uri": "/contracts/fF5AoXOTwNf#expert-panel", "label": "Supply Agreement (Acorda Therapeutics Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "disputes-between-the-parties", "type": "clause", "offset": [60, 88]}, {"key": "this-agreement", "type": "clause", "offset": [95, 109]}, {"key": "in-accordance-with", "type": "definition", "offset": [180, 198]}, {"key": "the-provisions", "type": "clause", "offset": [199, 213]}, {"key": "of-the-license", "type": "clause", "offset": [247, 261]}], "size": 2, "hash": "0b701156996a7b04341c4823fde89b26", "id": 9}, {"snippet": "means a panel selected in accordance with the procedures set forth on Schedule 1.1(g).", "samples": [{"hash": "d0IpbLHBX3q", "uri": "/contracts/d0IpbLHBX3q#expert-panel", "label": "Stock Purchase and Asset Transfer Agreement (Cigna Corp)", "score": 21.0, "published": true}, {"hash": "6szb0NxbfBO", "uri": "/contracts/6szb0NxbfBO#expert-panel", "label": "Stock Purchase and Asset Transfer Agreement (Prudential Financial Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "a-panel", "type": "definition", "offset": [6, 13]}, {"key": "in-accordance-with", "type": "definition", "offset": [23, 41]}, {"key": "the-procedures", "type": "definition", "offset": [42, 56]}, {"key": "on-schedule", "type": "definition", "offset": [67, 78]}], "size": 2, "hash": "f32cf169b2f61dd5c98a07c9da15b18d", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVZXhwZXJ0LXBhbmVsIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Expert Panel", "snippet": "has the meaning set forth in Section 3.5.3 (Decision-Making).", "size": 59, "id": "expert-panel", "examples": ["All members of the <strong>Expert Panel</strong> must be mutually agreed by the Parties in good faith and as promptly as possible and must be free of any conflicts of interest with respect to either or both Parties.", "The <strong>Expert Panel</strong> shall be constituted and called upon only when required within thirty (30) Days from receipt of a Party of the written notice of the other Party\u2019s decision to refer a matter to the <strong>Expert Panel</strong>.", "All <strong>Expert Panel</strong> and arbitral awards shall be in writing and shall state the reasons upon which they are based.", "The members of the <strong>Expert Panel</strong> shall develop their own internal conduct and procedural rules based upon principles of transparency, impartiality, and efficiency.", "Proceedings of the <strong>Expert Panel</strong> shall not be required to follow the procedural laws related to arbitrations.", "Each of the SRN Majority Holders and the Company agree that the Independent <strong>Expert Panel</strong> shall consist of one (1) nominee appointed by each party.", "Except as otherwise expressly provided in this Agreement, all decisions of the <strong>Expert Panel</strong> shall be taken within not more than sixty (60) Days after the receipt by the <strong>Expert Panel</strong> of a request by either Party for a decision of the <strong>Expert Panel</strong> pursuant to this Agreement or by such later time as may be agreed by the Parties.", "The determination of the relevant <strong>Expert Panel</strong> as to such dispute will be binding on both Parties.", "The <strong>Expert Panel</strong> need not be bound by strict rules of law where it considers the application thereof to particular matters to be inconsistent with the spirit of this Agreement and the underlying intent of the Parties.", "Each of the SRN Majority Holders and the Company shall use its best efforts to appoint a suitable nominee (being an experienced global pharmaceutical executive with qualifications consistent with those of other directors of the Company) and procure that the Independent <strong>Expert Panel</strong> considers the Deadlock and delivers its determination (the \u201cExpert Solution\u201d) of how to resolve the Deadlock within twenty (20) business days of service of the Second Level Notice."], "related": [["appraiser-panel", "Appraiser panel", "Appraiser panel"], ["expert", "Expert", "Expert"], ["arbitration-panel", "Arbitration Panel", "Arbitration Panel"], ["dsx-panel", "DSX Panel", "DSX Panel"], ["independent-expert", "Independent Expert", "Independent Expert"]], "related_snippets": [], "updated": "2025-07-10T05:58:13+00:00"}, "json": true, "cursor": ""}}